Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Regulski

Podiatrist, Foot & Ankle Surgery Toms River, NJ Doctor of Podiatric Medicine

NPI 1295737344 CMS profile 149103

54 Bey Lea Rd, Suite 1, Toms River, NJ 08753

Open in the dashboard

General payments

$843,271

400 records reported · program years 2019–2025

Research payments

$13,950

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,750 paid to institutions, not to them · program year 2019

Through program year 2025, Matthew Regulski of Toms River, NJ is reported in the CMS Open Payments database as having received $843,271 across 400 general payments and $13,950 in research payments paid to them. Separately, studies naming them as principal investigator received $3,750 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122,325 29
2024 General $101,012 42
2023 General $21,629 75
2022 General $203,868 88
2021 General $155,280 44
2020 General $143,929 24
2019 General $95,228 98
2019 Research $13,950 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Regulski
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Matthew Regulski were reported at $122,325. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Matthew Regulski Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $95,228 $389 $118–$1,406 $163
2020 $143,929 $191 $62–$691 $114
2021 $155,280 $329 $104–$1,341 $132
2022 $203,868 $419 $125–$1,611 $149
2023 $21,629 $377 $128–$1,164 $160
2024 $101,012 $394 $134–$1,168 $164
2025 $122,325 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Next Science LLC $730,194 161 payments
  2. Musculoskeletal Transplant Foundation Inc. $49,905 48 payments
  3. Smith+Nephew, Inc. $31,720 65 payments
  4. Advanced Oxygen Therapy Inc. $10,628 8 payments
  5. Osiris Therapeutics Inc. $8,583 15 payments
  6. Biocomposites Inc $6,523 7 payments
  7. Organogenesis Inc. $1,475 21 payments
  8. Triad Life Sciences Inc. $1,411 3 payments
  9. ConvaTec Inc. $427 5 payments
  10. AbbVie, Inc. $384 23 payments
  11. Other $2,019 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $781,096 73 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,725 15 payments
  3. Travel and Lodging $16,414 52 payments
  4. Food and Beverage $15,835 259 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $1,200 1 payment
Products named General payments · program years 2019–2025
  1. BlastX Wound Care $458,097 60 payments
  2. SurgX Surgical Site Infection $329,419 46 payments
  3. Xperience Surgical Site Infection $329,419 46 payments
  4. SurgX Wound Care $128,678 14 payments
  5. Xperience Wound Care $128,678 14 payments
  6. XPERIENCE surgical infection $108,916 5 payments
  7. BlastX surgical infection $108,916 5 payments
  8. BLASTX surgical infection $79,746 4 payments
  9. BlastX Wounds $64,958 38 payments
  10. STRAVIX $20,556 25 payments
  11. Other $156,339 439 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Osiris Therapeutics Inc. $9,750 1 payment
  2. Musculoskeletal Transplant Foundation Inc. $4,200 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

208

Median for Podiatry: 160

Drug cost

$2,548

Median for Podiatry: $2,368

Branded share of claims

48.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Ciclopirox Olamine Brand 84 $1,541
Triamcinolone Acetonide Generic 52 $609
Tramadol Hcl Generic 55 $237
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 17 $161

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$610,195

Medicare's payments for the services billed

Medicare patients

203

Average age 77

Services billed

6,428

93 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 71%
Ischemic heart disease 56%
Chronic kidney disease 44%
Atrial fibrillation 37%
COPD 35%
Heart failure 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $43
$43 — —
TEFLARO
  • AbbVie, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

402 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record